EGFR and non-small cell lung carcinoma: In this study [10] patients’ smoking habits were also examined, and it is suggested that NSCLC subgroups (never-smokers EGFR wild type and smokers with EGFR mutant) could benefit from nivolumab treatment and the reason could be a different mutational burden or PD-L1 expression.